Harvard Bioscience Inc Revenue Growth Rates (HBIO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Harvard Bioscience Inc   (NASDAQ: HBIO)
 

HBIO's Revenue Growth by Quarter and Year

Harvard Bioscience Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HBIO/growth
https://api.csimarket.com/api/v1/companies/HBIO/fundamentals
https://api.csimarket.com/api/v1/companies/HBIO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
HBIO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 22.20
2nd Quarter June 22.73
1st Quarter March 20.24
FY 65.17

HBIOs Annual Revenue
Harvard Bioscience Inc 's Revenue in the fiscal year 2025 $ 85.91 millions
Harvard Bioscience Inc 's Revenue in the fiscal year 2024 $ 93.77 millions
Harvard Bioscience Inc 's Revenue in the fiscal year 2023 $ 112.07 millions
Harvard Bioscience Inc 's Revenue in the fiscal year 2022 $ 113.34 millions
Harvard Bioscience Inc 's Revenue in the fiscal year 2021 $ 118.90 millions




HBIO Revenue third quarter 2026 Y/Y Growth Comment
Harvard Bioscience Inc achieved in the third quarter 2026, above Company average Revenue increase of 10.87% year on year, to $ 22.20 millions.

Looking into third quarter 2026 results within Laboratory Analytical Instruments industry 4 other companies have achieved higher Revenue growth. While Harvard Bioscience Inc ' s Revenue growth of 10.87% ranks overall at the positon no. 1224 in the third quarter 2026.


HBIO Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.87 %
2nd Quarter June 16.39 %
1st Quarter March -4.44 %
FY   -

Financial Statements
Harvard Bioscience Inc 's third quarter 2026 Revenue $ 22.20 millions HBIO's Income Statement
Harvard Bioscience Inc 's third quarter 2025 Revenue $ 20.02 millions Quarterly HBIO's Income Statement


HBIO Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -2.35 %
2nd Quarter June 12.3 %
1st Quarter March -19.59 %
FY (Year on Year)   -


Back to HBIO Growth rate Comparisons >> Back to HBIO Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #5
Healthcare Sector #224
Overall #1224

Revenue Y/Y Growth Statistics
High Average Low
66.27 % 0.15 % -32.92 %
(Dec 31 2018)   (Dec 31 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #5
Healthcare Sector #224
Overall #1224
Revenue Y/Y Growth Statistics
High Average Low
66.27 % 0.15 % -32.92 %
(Dec 31 2018)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Harvard Bioscience Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
28.9 % 0.57 % -31.53 %
(Dec 31 2020)  


HBIO's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Harvard Bioscience Inc disclosed fall in Revenue from the second quarter by -2.35% to $ 22.20 millions, from $ 22.73 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Laboratory Analytical Instruments's company achievement, Most analysts pointed out.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Harvard Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 732.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #122
Overall #732
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #122
Overall #732
Revenue Q/Q Growth Statistics
High Average Low
28.9 % 0.57 % -31.53 %
(Dec 31 2020)  


HBIO's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Harvard Bioscience Inc disclosed fall in Revenue from the second quarter by -2.35% to $ 22.20 millions, from $ 22.73 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Laboratory Analytical Instruments's company achievement, Most analysts pointed out.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Harvard Bioscience Inc 's Revenue growth quarter on quarter, overall rank is 732.


Harvard Bioscience Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 90.34
Y / Y Revenue Growth (TTM) 4.14 %
Year on Year Revenue Growth Overall Ranking # 3190
Seqeuential Revenue Change (TTM) 2.47 %
Seq. Revenue Growth (TTM) Overall Ranking # 2889


Cumulative Revenue growth Comment
Harvard Bioscience Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 4.14% year on year, to $ 90 millions if the fiscal year would have ended in Sep 30 2026.
Harvard Bioscience Inc 's trailing twelve months Revenue growth was higher than company's average -1.14% and higher than -0.37% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 2.47 % from $88.16 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -0.65%.

In the Healthcare sector 427 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2340 to 3190.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 18
Healthcare Sector # 428
Overall # 3190

Revenue TTM Y/Y Growth Statistics
High Average Low
25.72 %
 -1.14 %
-16.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 406
S&P 500 # 2889
Cumulative Revenue growth Comment
Harvard Bioscience Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 4.14% year on year, to $ 90 millions if the fiscal year would have ended in Sep 30 2026.
Harvard Bioscience Inc 's trailing twelve months Revenue growth was higher than company's average -1.14% and higher than -0.37% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 2.47 % from $88.16 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -0.65%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 2.47 % increase from $88.16 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 427 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2340 to 3190.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 18
Healthcare Sector # 428
Overall # 3190

Revenue TTM Y/Y Growth Statistics
High Average Low
25.72 %
-1.14 %
-16.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 406
S&P 500 # 2889




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HBIO's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Harvard Apparatus Regenerative Technology Inc 17.89%$ 17.886 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions


About Harvard Bioscience Inc Revenue Growth Rates (HBIO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Harvard Bioscience Inc (CIK 1123494).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001171843-26-007336
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Harvard Bioscience Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.